77 related articles for article (PubMed ID: 9131142)
1. Heterocyclic alkylphospholipids with an improved therapeutic range.
Hilgard P; Stekar J; Klenner T; Nössner B; Kutscher B; Engel J
Adv Exp Med Biol; 1996; 416():157-64. PubMed ID: 9131142
[No Abstract] [Full Text] [Related]
2. Alkylphospholipids reversibly open epithelial tight junctions.
Leroy A; de Bruyne GK; Oomen LC; Mareel MM
Anticancer Res; 2003; 23(1A):27-32. PubMed ID: 12680191
[TBL] [Abstract][Full Text] [Related]
3. Anticancer mechanisms and clinical application of alkylphospholipids.
van Blitterswijk WJ; Verheij M
Biochim Biophys Acta; 2013 Mar; 1831(3):663-74. PubMed ID: 23137567
[TBL] [Abstract][Full Text] [Related]
4. Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapy.
Vink SR; van Blitterswijk WJ; Schellens JH; Verheij M
Cancer Treat Rev; 2007 Apr; 33(2):191-202. PubMed ID: 17287087
[TBL] [Abstract][Full Text] [Related]
5. Experimental therapeutic studies with miltefosine in rats and mice.
Hilgard P; Stekar J; Voegeli R; Harleman JH
Prog Exp Tumor Res; 1992; 34():116-30. PubMed ID: 1438794
[No Abstract] [Full Text] [Related]
6. New pharmaceuticals: miltefosine.
Hilgard P
Anticancer Drugs; 1990 Dec; 1(2):185. PubMed ID: 2131052
[No Abstract] [Full Text] [Related]
7. Alkylphospholipids - a promising class of chemotherapeutic agents with a broad pharmacological spectrum.
Pachioni Jde A; Magalhães JG; Lima EJ; Bueno Lde M; Barbosa JF; de Sá MM; Rangel-Yagui CO
J Pharm Pharm Sci; 2013; 16(5):742-59. PubMed ID: 24393556
[TBL] [Abstract][Full Text] [Related]
8. Dialkylamino and nitrogen heterocyclic analogues of hexadecylphosphocholine and cetyltrimetylammonium bromide: effect of phosphate group and environment of the ammonium cation on their biological activity.
Lukác M; Mojzis J; Mojzisová G; Mrva M; Ondriska F; Valentová J; Lacko I; Bukovský M; Devínsky F; Karlovská J
Eur J Med Chem; 2009 Dec; 44(12):4970-7. PubMed ID: 19762125
[TBL] [Abstract][Full Text] [Related]
9. Miltefosine in recurrent cutaneous breast cancer.
Clive S; Leonard RC
Lancet; 1997 Mar; 349(9052):621-2. PubMed ID: 9057742
[No Abstract] [Full Text] [Related]
10. Alkylphospholipids inhibit capillary-like endothelial tube formation in vitro: antiangiogenic properties of a new class of antitumor agents.
Zerp SF; Vink SR; Ruiter GA; Koolwijk P; Peters E; van der Luit AH; de Jong D; Budde M; Bartelink H; van Blitterswijk WJ; Verheij M
Anticancer Drugs; 2008 Jan; 19(1):65-75. PubMed ID: 18043131
[TBL] [Abstract][Full Text] [Related]
11. [[Treatment with Miltex for metastatic skin lesions in breast cancer] ].
Moĭseenko VM; Orlova RV; Ermakova NA; Protsenko SA
Vopr Onkol; 2000; 46(5):600-3. PubMed ID: 11202195
[TBL] [Abstract][Full Text] [Related]
12. New cytostatics with experimentally different toxic profiles.
Berger MR; Muschiol C; Schmähl D; Eibl HJ
Cancer Treat Rev; 1987 Dec; 14(3-4):307-17. PubMed ID: 3440252
[No Abstract] [Full Text] [Related]
13. [Pharmacological properties of mono- and bisquanylhydrazones].
Wollert U
Arzneimittelforschung; 1969 Apr; 19(4):680-3. PubMed ID: 4894141
[No Abstract] [Full Text] [Related]
14. Loco-regional control of cutaneous metastases of malignant melanoma by treatment with miltefosine (Miltex).
Ragnarsson-Olding B; Djureen-Mårtensson E; Månsson-Brahme E; Hansson J
Acta Oncol; 2005; 44(7):773-7. PubMed ID: 16227173
[No Abstract] [Full Text] [Related]
15. Diapeutic cancer-targeting alkylphosphocholine analogs may advance management of brain malignancies.
Zhang RR; Swanson KI; Hall LT; Weichert JP; Kuo JS
CNS Oncol; 2016 Oct; 5(4):223-31. PubMed ID: 27616199
[TBL] [Abstract][Full Text] [Related]
16. Preface.
Prudhomme M
Anticancer Agents Med Chem; 2017; 17(1):3. PubMed ID: 28143384
[No Abstract] [Full Text] [Related]
17. Lipid rafts and metabolic energy differentially determine uptake of anti-cancer alkylphospholipids in lymphoma versus carcinoma cells.
Vink SR; van der Luit AH; Klarenbeek JB; Verheij M; van Blitterswijk WJ
Biochem Pharmacol; 2007 Nov; 74(10):1456-65. PubMed ID: 17803969
[TBL] [Abstract][Full Text] [Related]
18. Overview.
Prudhomme M
Anticancer Agents Med Chem; 2017; 17(1):2. PubMed ID: 28143383
[No Abstract] [Full Text] [Related]
19. Induction of resistance in the human leukemia cell line HL60 towards hexadecylphosphocholine and other ether phospholipid analogues.
Berkovic D; Haase D; Hiddemann W; Fleer EA
J Exp Ther Oncol; 1996 Nov; 1(6):368-75. PubMed ID: 9414427
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer.
Van Ummersen L; Binger K; Volkman J; Marnocha R; Tutsch K; Kolesar J; Arzoomanian R; Alberti D; Wilding G
Clin Cancer Res; 2004 Nov; 10(22):7450-6. PubMed ID: 15569974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
